EU marketing authorization granted for three new type 2 diabetes therapies, Vipidia, Vipdomet and Incresync
Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for Vipidia[TM] (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies[1]-[3]and for the fixed-dose combination (FDC) therapies Vipdomet[TM] (alogliptin with metformin) and Incresync[TM] (alogliptin with pioglitazone)...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Diabetes Source Type: news
More News: Actos | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Health | Marketing | Metformin